ROMANIELLO, DONATELLA
 Distribuzione geografica
Continente #
NA - Nord America 869
EU - Europa 831
AS - Asia 366
AF - Africa 16
SA - Sud America 1
Totale 2.083
Nazione #
US - Stati Uniti d'America 867
IT - Italia 442
SG - Singapore 193
CN - Cina 128
DE - Germania 90
IE - Irlanda 85
SE - Svezia 60
GB - Regno Unito 53
AT - Austria 17
FI - Finlandia 16
BG - Bulgaria 13
NL - Olanda 13
ES - Italia 11
ID - Indonesia 11
JO - Giordania 10
CH - Svizzera 9
TG - Togo 9
CI - Costa d'Avorio 7
FR - Francia 7
IR - Iran 6
RU - Federazione Russa 6
DK - Danimarca 4
HK - Hong Kong 4
IN - India 4
BD - Bangladesh 2
BE - Belgio 2
IL - Israele 2
JP - Giappone 2
TW - Taiwan 2
BR - Brasile 1
CA - Canada 1
CU - Cuba 1
GR - Grecia 1
PL - Polonia 1
RO - Romania 1
TR - Turchia 1
UZ - Uzbekistan 1
Totale 2.083
Città #
Bologna 223
Singapore 180
Chandler 123
Santa Clara 123
Dublin 82
Princeton 72
Boardman 54
Ashburn 42
Berlin 38
Southend 37
Fairfield 33
Medford 23
Munich 21
Milan 20
Los Angeles 19
Modena 18
Beijing 17
Vienna 17
Rome 16
Seattle 15
Guangzhou 13
Helsinki 13
Sofia 13
Jakarta 11
London 11
New York 11
Amman 10
Bremen 10
Woodbridge 10
Bern 9
Lomé 9
Olalla 9
Marcon 8
Naples 8
San Diego 8
Shanghai 8
Abidjan 7
Boydton 7
Cambridge 7
Florence 7
Forlì 7
Redmond 7
Reggio Emilia 7
Stanford 7
Wilmington 7
Brescia 6
Jinan 6
Alicante 5
Amsterdam 5
Falkenstein 5
Ferrara 5
Houston 5
Ann Arbor 4
Bronshoj 4
Markaz 4
Padova 4
Phoenix 4
Turin 4
Carpi 3
Hong Kong 3
Ithaca 3
Kilburn 3
Lappeenranta 3
Maastricht 3
Mérignac 3
Mülheim 3
Picerno 3
Qingdao 3
Siena 3
Soliera 3
Tianjin 3
Wenzhou 3
Xi'an 3
Arzano 2
Bresso 2
Brussels 2
Campobasso 2
Caravaggio 2
Castelfranco Veneto 2
Castiglione dei Pepoli 2
Changsha 2
Chicago 2
Columbus 2
Dhaka 2
Formigine 2
Groningen 2
Hangzhou 2
Harbin 2
Hyderabad 2
Imola 2
Madrid 2
Montecatini Terme 2
Ningbo 2
Novara 2
Orzinuovi 2
Rehovot 2
Riccione 2
Taipei 2
Taizhou 2
Wageningen 2
Totale 1.557
Nome #
Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies 122
CEA Cell Adhesion Molecule 6 (CEACAM6), Collagen Type I Alpha 2 Chain (COL1A2), Galectin 4 (LGALS4) and Tetraspanin 8 (TSPAN8) mRNAs as blood biomarkers for colorectal cancer 106
IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy 101
Extracellular Vesicles and Epidermal Growth Factor Receptor Activation: Interplay of Drivers in Cancer Progression 97
ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma 93
Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization 88
The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in Consensus Molecular Subtype 1 colon cancer 78
NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells 77
MET receptor regulates perinuclear actin cap remodeling through YAP1 inactivation 72
The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer 68
Aberrant MET activation impairs perinuclear actin cap organization with YAP1 cytosolic relocation 66
BMP7 promotes cardiomyocyte regeneration in zebrafish and adult mice 63
Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies 60
IL-1 Associated Post Senescence Reprogramming Impairs Response To EGFR Neutralization 51
Cancer Immunotherapy: The Dawn of Antibody Cocktails 47
null 46
JAK2-Regulation Of HER2 “Addiction” In HER2-Positive Breast Cancer Cell Lines 41
Senescence-associated reprogramming impairs response to EGFR neutralization 39
β-Hexachlorocyclohexane Drives Carcinogenesis in the Human Normal Bronchial Epithelium Cell Line BEAS-2B 38
Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies 37
Biochemical characterization of the ERp57-STAT3 complex 36
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors 35
Functional Studies Of Stat3 And Its Interactors In Breast Cancer 35
MET receptor regulates perinuclear actin cap remodeling through YAP1 inactivation 34
Comparative analysis of the interaction between different flavonoids and pdia3 33
First-line therapy based on kinase inhibitors and antibodies prevents resistance in egfr-mutated lung cancer. 33
Analysis of stat3 post-translational modifications (ptms) in human prostate cancer with different gleason scores 32
PDL1 immunohistochemistry in canine neoplasms: Validation of commercial antibodies, standardization of evaluation, and scoring systems 30
Targeting anaplastic lymphoma kinase in consensus molecular subtype 1 colon cancer patients 30
Synergy Between Kinase Inhibitors And Antibodies Enables Upfront Prevention Of Recurring Secondary Resistance In Egfr-Mutated Lung Cancer 29
A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways 29
Dangerous liaison: organochlorine substances, energy metabolism and cancer 29
The natural sesquiterpene β- caryophyllene acts as an enviromental decontaminant through the interference with the STAT3 signalling pathway 29
A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib 28
Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models 28
PARP-1 as coactivator of STAT3 in M14 melanoma cell line 28
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor 28
Interaction between flavonoids and PDIA3 27
Acetylation and phosphorylation of STAT3 are involved in the responsiveness of microglia to beta amyloid 26
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab 24
STAT3 post-translational modifications drive cellular signaling pathways in prostate cancer cells 24
β-Caryophyllene Counteracts Chemoresistance Induced by Cigarette Smoke in Triple-Negative Breast Cancer MDA-MB-468 Cells 23
EGFR/STAT3/ERp57 Interplay in human prostate cancer progression 23
Senescence-associated reprogramming impairs response to EGFR neutralization 22
Protease, an Advance Therapeutic Target in Cancer 22
STAT3/ERP57/TPX2 axis and process of “androgen escape” in prostate cancer 18
STAT3--ERp57 Interplay in human prostate cancer 17
STAT3-EGFR PATHWAY IN NEUROENDOCRINE PROSTATE CANCER: A CASE REPORT 17
STAT3's role in microglial cells 17
null 4
Totale 2.180
Categoria #
all - tutte 9.071
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.071


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202029 0 0 0 0 0 0 3 14 7 2 1 2
2020/202171 3 19 24 0 3 3 6 1 4 3 1 4
2021/2022310 0 3 0 0 3 3 1 36 45 18 123 78
2022/2023664 56 62 27 61 74 56 17 61 131 10 56 53
2023/2024373 44 44 36 30 22 67 14 27 14 28 16 31
2024/2025733 34 186 134 96 211 72 0 0 0 0 0 0
Totale 2.180